共 46 条
[1]
Remon J(2015)Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies Cancer Treat Rev 41 27-34
[2]
Reguart N(2013)The worldwide pandemic of asbestos-related diseases Annu Rev Public Health 34 205-216
[3]
Corral J(2010)Living with mesothelioma. A literature review Eur J Cancer Care 19 458-468
[4]
Lianes P(2005)Mesothelioma from the patient’s perspective Hematol Oncol Clin North Am 19 1175-1190
[5]
Stayner L(2009)Use of existing patient-reported outcome (pro) instruments and their modification: the ispor good research practices for evaluating and documenting content validity for the use of existing instruments and their modification pro task force report Value Health 12 1075-1083
[6]
Welch LS(2009)Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims Fed Regist 74 65132-65133
[7]
Lemen R(2006)Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 14 11-21
[8]
Moore S(2004)Adapting the lung cancer symptom scale (LCSS) to mesothelioma: using the LCSS-meso conceptual model for validation Cancer 101 587-595
[9]
Darlison L(2013)Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL) Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 21 165-172
[10]
Tod AM(2011)Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (pro) instruments for medical product evaluation: Ispor Progood Research Practices Task Force report: part 1—eliciting concepts for a new pro instrument Value Health 14 967-977